Current sepsis therapeutic strategies targeting the fibrinolytic system focus on thrombolytic drugs (such as Antithrombin‐III [37] and Recombinant human soluble thrombomodulin (rhTM) [38]) and antifibrinolytic drugs (such as tranexamic acid [39] and aminocaproic acid [40]). The gene discussed is THBD; the disease is Sepsis.